Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

MLA

Yasuhiro Nakamura, et al. “Efficacy Comparison between Anti-PD-1 Antibody Monotherapy and Anti-PD-1 plus Anti-CTLA-4 Combination Therapy as First-Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients.” European Journal of Cancer, vol. 176, Nov. 2022, pp. 78–87. EBSCOhost, https://doi.org/10.1016/j.ejca.2022.08.030.

APA

Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, … Naoya Yamazaki. (2022). Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients. European Journal of Cancer, 176, 78–87. https://doi.org/10.1016/j.ejca.2022.08.030

Chicago

Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, et al. 2022. “Efficacy Comparison between Anti-PD-1 Antibody Monotherapy and Anti-PD-1 plus Anti-CTLA-4 Combination Therapy as First-Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients.” European Journal of Cancer 176 (November): 78–87. doi:10.1016/j.ejca.2022.08.030.